https://www.live-feeds.com/feed/eli-lilly-and-company-lly-ceo-on-how-glp-1s-will-reshape-americaContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/eli-lilly-and-company-lly-ceo-on-how-glp-1s-will-reshape-americahttps://www.live-feeds.com/feed/eli-lilly-and-company-lly-ceo-on-how-glp-1s-will-reshape-america#u18525Tue, 30 Jun 2026 08:00:48 +0000Eli Lilly CEO David Ricks asserts that GLP-1 drugs will be more transformative than artificial intelligence. The company currently controls 60% of the GLP-1 market following a 125% revenue surge for Mounjaro. New oral GLP-1 medications are also in development to move beyond injections.What's confirmed:Eli Lilly CEO David Ricks stated on June 5 that GLP-1 drugs will be a more transformative technology than artificial intelligence.David Ricks described artificial intelligence as overhyped and GLP-1s as underhyped.Eli Lilly controls 60% of the GLP-1 market.Mounjaro revenue increased by 125% accor